

# CITATION REPORT

List of articles citing

**On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction**

**DOI: 10.1038/sj.ijir.3900631**

**International Journal of Impotence Research, 2001, 13, 2-9.**

**Source:** <https://exaly.com/paper-pdf/33206772/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
193	Modern pharmacotherapy for erectile dysfunction: evolving concepts with central and peripheral acting agents. <b>2001</b> , 11, 625-30		2
192	Current World Literature. <b>2001</b> , 11, 637-656		
191	Current treatments and emerging therapeutic approaches in male erectile dysfunction. <i>BJU International</i> , <b>2001</b> , 88 Suppl 3, 11-7	5.6	21
190	Pharmacotherapy of erectile dysfunction. <i>Sexual and Relationship Therapy</i> , <b>2002</b> , 17, 389-400	1.1	0
189	Effects of tadalafil on erectile dysfunction in men with diabetes. <b>2002</b> , 25, 2159-64		206
188	Tadalafil: a novel treatment for erectile dysfunction. <b>2002</b> , 4, H24-H31		13
187	Erectile dysfunction in patients with diabetes mellitus Advances in treatment with phosphodiesterase type 5 inhibitors. <b>2002</b> , 2, 282-287		8
186	Current World Literature. <b>2002</b> , 12, 517-523		
185	Moderators Introduction. <b>2002</b> , 4, H1-H6		2
184	Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. <b>2002</b> , 105, 2398-403		508
183	Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated Analyses. <i>Journal of Urology</i> , <b>2002</b> , 168, 1332-1336	2.5	429
182	[Erectile dysfunction]. <b>2002</b> , 26, 667-90		5
181	Type 5 phosphodiesterase expression in the human vagina. <i>Urology</i> , <b>2002</b> , 60, 191-5	1.6	125
180	Topical alprostadil cream for the treatment of erectile dysfunction: a combined analysis of the phase II program. <i>Urology</i> , <b>2002</b> , 60, 1077-82	1.6	18
179	What Do Patients Expect from Erectile Dysfunction Therapy?. <b>2002</b> , 1, 4-11		16
178	Tadalafil Phase 3 Experience. <b>2002</b> , 1, 25-30		
177	CNS-targeted sexual dysfunction drug for men and women. <b>2002</b> , 7, 492-3		1

176	IC351 (tadalafil, Cialis): update on clinical experience. <i>International Journal of Impotence Research</i> , <b>2002</b> , 14 Suppl 1, S57-64	2.3	82
175	The International Index of Erectile Function (IIEF): a state-of-the-science review. <i>International Journal of Impotence Research</i> , <b>2002</b> , 14, 226-44	2.3	718
174	Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. <i>International Journal of Impotence Research</i> , <b>2002</b> , 14, 466-71	2.3	84
173	Effects of sildenafil on erectile activity in mice lacking neuronal or endothelial nitric oxide synthase. <i>British Journal of Pharmacology</i> , <b>2002</b> , 136, 693-700	8.6	46
172	The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. <b>2003</b> , 8, 5-21		51
171	[How effective are PDE-5 inhibitors?]. <b>2003</b> , 42, 553-8		4
170	Cardiovascular effects of tadalafil. <b>2003</b> , 92, 37M-46M		98
169	Overview of phosphodiesterase 5 inhibition in erectile dysfunction. <b>2003</b> , 92, 9M-18M		160
168	Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. <b>2003</b> , 92, 19M-25M		88
167	Pharmacological management of erectile dysfunction. <i>BJU International</i> , <b>2003</b> , 91, 446-54	5.6	74
166	Activation and potentiation of the NO/cGMP pathway by NG-hydroxyl-L-arginine in rabbit corpus cavernosum under normoxic and hypoxic conditions and ageing. <i>British Journal of Pharmacology</i> , <b>2003</b> , 138, 63-70	8.6	22
165	The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED. <i>International Journal of Impotence Research</i> , <b>2003</b> , 15, 10-7	2.3	31
164	Inflatable penile prosthesis: site-specific malfunction analysis. <i>International Journal of Impotence Research</i> , <b>2003</b> , 15, 22-5	2.3	15
163	Vardenafil enhances clitoral and vaginal blood flow responses to pelvic nerve stimulation in female dogs. <i>International Journal of Impotence Research</i> , <b>2003</b> , 15, 137-41	2.3	28
162	Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey. <i>International Journal of Impotence Research</i> , <b>2003</b> , 15 Suppl 5, S13-9	2.3	15
161	Oral drug treatment of erectile dysfunction. <i>International Journal of Impotence Research</i> , <b>2003</b> , 15 Suppl 7, S27-9	2.3	1
160	Optimizing treatment for diabetes mellitus induced erectile dysfunction. <i>Journal of Urology</i> , <b>2003</b> , 170, S35-8; discussion S39	2.5	45
159	Implications of diabetes mellitus in urology. <b>2003</b> , 30, 1-12		70

158	Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment. <i>Journal of Urology</i> , <b>2003</b> , 169, 1999-2007	2.5	82
157	Tadalafil. <b>2003</b> , 63, 2203-12; discussion 2213-4		57
156	Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF. <b>2003</b> , 312, 1202-8		89
155	Cyclic GMP phosphodiesterases and regulation of smooth muscle function. <b>2003</b> , 93, 280-91		420
154	New achievements and pharmacotherapeutic approaches to impotence in the elderly. <b>2003</b> , 15, 222-33		2
153	Phosphodiesterase type 5 (PDE5) inhibitors. <b>2003</b> , 41, 249-306		23
152	Review of tadalafil in the treatment of erectile dysfunction. <b>2003</b> , 4, 2049-56		16
151	Cialis (tadalafil): a new treatment for erectile dysfunction. <b>2003</b> , 64, 589-92		2
150	Phosphodiesterase 5 inhibitors in male sexual dysfunction. <b>2003</b> , 13, 405-10		13
149	Pharmacologic management of sexual dysfunction: benefits and limitations. <b>2003</b> , 8, 225-9		5
148	Erectile Dysfunction in the Elderly: Epidemiology, Etiology, and Approaches to Treatment. <b>2004</b> , 241-254		1
147	Emerging oral drugs for erectile dysfunction. <b>2004</b> , 9, 179-189		4
146	From Informed Consent through Database Lock: An Interactive Clinical Trial Conducted Using the Internet. <b>2004</b> , 38, 239-251		7
145	Tadalafil: A Comprehensive Update. <b>2004</b> , 2, 225-246		
144	Advances in the Treatment of Erectile Dysfunction: A Focus on Tadalafil. <b>2004</b> , 17, 239-250		1
143	The Role of the NO Axis and its Therapeutic Implications in Pulmonary Arterial Hypertension. <b>2004</b> , 213-229		
142	Treatment of erectile dysfunction. <b>2004</b> , 15, 215-21		7
141	Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction. <i>BJU International</i> , <b>2004</b> , 94, 871-7	5.6	39

140	Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. <b>2004</b> , 61, 382-6		95
139	Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. <i>International Journal of Impotence Research</i> , <b>2004</b> , 16, 135-42	2.3	67
138	Pharmacotherapy for erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2004</b> , 1, 128-40	1.1	27
137	Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study. <i>Journal of Sexual Medicine</i> , <b>2004</b> , 1, 201-8	1.1	23
136	A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. <i>European Urology</i> , <b>2004</b> , 45, 499-507; discussion 507-9	10.2	76
135	Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. <i>European Urology</i> , <b>2004</b> , 46, 362-9; discussion 369	10.2	48
134	Therapy of ED: PDE-5 Inhibitors. <b>2004</b> , 23, 135-41		24
133	Population dose-response model for tadalafil in the treatment of male erectile dysfunction. <b>2004</b> , 21, 1463-70		10
132	Diabetes and erectile dysfunction. <b>2004</b> , 1, 87-91		2
131	Erectile dysfunction: etiology, evaluation, and treatment options. <b>2004</b> , 88, 387-416, xi		8
130	Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. <i>Journal of Urology</i> , <b>2004</b> , 172, 1036-41	2.5	176
129	Integrated analysis examining first-dose success, success by dose, and maintenance of success among men taking tadalafil for erectile dysfunction. <i>Urology</i> , <b>2004</b> , 64, 783-8	1.6	25
128	Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). <b>2004</b> , 45, 859-63		74
127	Therapeutic interventions targeting the nitric oxide system: current and potential uses in obstetrics, bone disease and erectile dysfunction. <b>2004</b> , 74, 1701-21		5
126	Erectile dysfunction: evaluation and new treatment options. <b>2004</b> , 66, 664-71		29
125	Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2004</b> , 1, 185-196		
124	Evaluation of sexual activity in patients treated with tadalafil: a randomized prospective placebo-controlled trial. <i>International Journal of Impotence Research</i> , <b>2005</b> , 17, 76-9	2.3	6
123	A 6-month study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: a randomised, double-blind, parallel-group, placebo-controlled study in Australian men. <i>International Journal of Clinical Practice</i> , <b>2005</b> , 59, 143-9	2.9	14

122	The therapeutic dilemma: how to use tadalafil. <b>2005</b> , 28 Suppl 2, 74-80		36
121	Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial. <i>Journal of Sexual Medicine</i> , <b>2005</b> , 2, 685-98	1.1	22
120	Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. <b>2005</b> , 23, 374-84		25
119	Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction. <b>2005</b> , 5, 18		43
118	Evaluation of Sexual Activity in Patients Treated with Tadalafil: A Randomized Prospective Placebo-Controlled Trial. <b>2005</b> , 72, 177-179		
117	Tadalafil: a clinical update. <i>Aging Health</i> , <b>2005</b> , 1, 203-214		3
116	Tadalafil. <b>2005</b> , 85-107		
115	Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. <b>2005</b> , 2, 239-47		40
114	Erectile dysfunction: anatomical parameters, etiology, diagnosis, and therapy. <b>2005</b> , 51, 15-31		23
113	Effect of tadalafil on sexual timing behavior patterns in men with erectile dysfunction: integrated analysis of randomized, placebo controlled trials. <i>Journal of Urology</i> , <b>2005</b> , 174, 1356-9	2.5	13
112	Oral Pharmacotherapy for Male Sexual Dysfunction. <b>2005</b> ,		
111	Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. <b>2005</b> , 6, 75-84		43
110	[Erectile dysfunction drugs and women]. <b>2005</b> , 33, 590-3		1
109	Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. <i>Urology</i> , <b>2005</b> , 65, 755-9	1.6	35
108	Vardenafil in patients with erectile dysfunction: achieving treatment optimization. <b>2005</b> , 26, 604-9		15
107	Chapter 1: The management of erectile dysfunction: an AUA update. <i>Journal of Urology</i> , <b>2005</b> , 174, 230-2.5		255
106	Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management. <b>2006</b> , 23, 101-17		37
105	Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. <b>2006</b> , 58, 488-520		1350

104	Effect of Epimedium brevicornum Maxim extract on elicitation of penile erection in the rat. <i>Urology</i> , <b>2006</b> , 67, 631-5	1.6	17
103	An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. <i>Urology</i> , <b>2006</b> , 68, 386-91	1.6	48
102	Through the eyes of women: the partners perspective on tadalafil. <i>Urology</i> , <b>2006</b> , 68, 631-5	1.6	31
101	Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study. <i>Urology</i> , <b>2006</b> , 68, 845-51	1.6	18
100	Management of the cardinal features of andropause. <b>2006</b> , 13, 145-60		19
99	Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-East Asian men. <b>2006</b> , 13, 721-7		12
98	Tadalafil pharmacokinetics in healthy subjects. <b>2006</b> , 61, 280-8		188
97	Sexual dysfunction after pelvic surgery. <i>International Journal of Impotence Research</i> , <b>2006</b> , 18, 1-18	2.3	67
96	Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations. <i>International Journal of Impotence Research</i> , <b>2006</b> , 18, 229-35	2.3	49
95	A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. <b>2006</b> , 66, 439-44		55
94	Rate constants for 1,n-hydrogen transfer reactions in some amino acid derived radicals. <b>2006</b> , 47, 7911-7914		10
93	Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. <i>European Urology</i> , <b>2006</b> , 50, 351-9	10.2	139
92	Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. <i>International Journal of Impotence Research</i> , <b>2007</b> , 19, 95-103	2.3	93
91	Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: an open-label extension of a blinded trial. <i>Urology</i> , <b>2007</b> , 70, 1190-3	1.6	27
90	Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. <i>International Journal of Impotence Research</i> , <b>2007</b> , 19, 281-95	2.3	33
89	Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. <i>BJU International</i> , <b>2007</b> , 100, 122-9	5.6	33
88	Efficacy of tadalafil in Egyptian and Turkish men with erectile dysfunction. <i>International Journal of Clinical Practice</i> , <b>2006</b> , 60, 812-9	2.9	8
87	Penile erection induced in vivo by a purified toxin from the Brazilian spider Phoneutria nigriventer. <i>BJU International</i> , <b>2008</b> , 102, 835-7	5.6	19

86	The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2008</b> , 5, 946-953	1.1	56
85	Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2008</b> , 5, 2672-80	1.1	60
84	Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. <i>Expert Opinion on Investigational Drugs</i> , <b>2008</b> , 17, 855-64	5.9	16
83	Twenty years of IJIR. <i>International Journal of Impotence Research</i> , <b>2008</b> , 20, 429-30	2.3	
82	Validated questionnaires for assessing sexual dysfunction and BPH/LUTS: solidifying the common pathophysiologic link. <i>International Journal of Impotence Research</i> , <b>2008</b> , 20 Suppl 3, S27-32	2.3	11
81	Solution structure of the cGMP binding GAF domain from phosphodiesterase 5: insights into nucleotide specificity, dimerization, and cGMP-dependent conformational change. <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 22749-59	5.4	31
80	Tadalafil in the treatment of lower urinary tract symptoms and erectile dysfunction. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2008</b> , 5, 355-365		2
79	Helping people with sexual problems. <b>2009</b> , 343-380		2
78	Effect of erectile dysfunction medications on coexisting sexual dysfunctions in couples: PartnersQ Preference Study. <i>Sexual and Relationship Therapy</i> , <b>2009</b> , 24, 316-332	1.1	1
77	Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. <i>Journal of Sexual Medicine</i> , <b>2009</b> , 6, 553-7	1.1	35
76	Complex pelvic floor failure and associated problems. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2009</b> , 23, 555-73	2.5	28
75	Tadalafil. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , <b>2009</b> , 26, 124-125		
74	Five-year experience with tadalafil in the UK: an effective treatment for erectile dysfunction. <i>International Journal of Clinical Practice</i> , <b>2009</b> , 63, 1231-6	2.9	
73	Cyclic GMP-hydrolyzing phosphodiesterases. <i>Handbook of Experimental Pharmacology</i> , <b>2009</b> , 367-408	3.2	28
72	cGMP: Generators, Effectors and Therapeutic Implications. <i>Handbook of Experimental Pharmacology</i> , <b>2009</b> ,	3.2	13
71	Diabetes, sexual dysfunction and therapeutic exercise: a 20 year review. <i>Current Diabetes Reviews</i> , <b>2010</b> , 6, 201-6	2.7	31
70	Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction. <b>2010</b> , 135-172		
69	Pharmacotherapy for erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 524-40	1.1	132

68	Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 1928-36	1.1	29
67	Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 2851-9	1.1	24
66	Cyclic Nucleotide-Binding GAF Domains in Phosphodiesterases and Adenylyl Cyclases. <b>2010</b> , 1531-1536		
65	Inhibidores de la fosfodiesterasa 5: calidad de la erección y repercusión emocional en los varones con disfunción eréctil y sus parejas. <i>Revista Internacional De Andrología</i> , <b>2010</b> , 8, 155-164	0.6	2
64	Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , <b>2011</b> , 51, 1071-8	2.9	16
63	Efficacy and tolerability of tadalafil for treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. <i>Urology</i> , <b>2011</b> , 77, 1137-41	1.6	22
62	Nueva formulación bucodispersable de vardenafilo para el tratamiento de la disfunción eréctil. <i>Revista Internacional De Andrología</i> , <b>2011</b> , 9, 21-29	0.6	
61	Patients' preference in the treatment of erectile dysfunction: a critical review of the literature. <i>International Journal of Impotence Research</i> , <b>2011</b> , 23, 1-8	2.3	17
60	The Subjective Sexual Arousal Scale for Men (SSASM): preliminary development and psychometric validation of a multidimensional measure of subjective male sexual arousal. <i>Journal of Sexual Medicine</i> , <b>2011</b> , 8, 2255-68	1.1	3
59	Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. <i>Annals of Internal Medicine</i> , <b>2012</b> , 157, 681-91	8	113
58	Considerations in the design of clinical trials for erectile dysfunction. <i>Clinical Investigation</i> , <b>2012</b> , 2, 733-745		0
57	Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 2618-27	15.1	67
56	Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial. <i>BJU International</i> , <b>2012</b> , 110, 1801-6	5.6	37
55	Ca <sup>2+</sup> -activated K <sup>+</sup> channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction. <i>British Journal of Pharmacology</i> , <b>2013</b> , 169, 449-61	8.6	34
54	Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. <i>European Urology</i> , <b>2013</b> , 63, 902-12	10.2	157
53	Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature. <i>World Journal of Men's Health</i> , <b>2014</b> , 32, 18-27	6.8	9
52	A broad-spectrum approach to daily tadalafil: making the big picture even bigger. <i>European Urology</i> , <b>2014</b> , 65, 465-6	10.2	
51	Temporal and spatial regulation of cAMP signaling in disease: role of cyclic nucleotide phosphodiesterases. <i>Fundamental and Clinical Pharmacology</i> , <b>2014</b> , 28, 593-607	3.1	18

50	Patients affected by premature ejaculation due to glans hypersensitivity refuse circumcision as a potential definite treatment for their problem. <i>Andrologia</i> , <b>2014</b> , 46, 349-55	2.4	5
49	Once-a-day Tadalafil administration improves the spermogram parameters in fertile patients. <i>Archivio Italiano Di Urologia Andrologia</i> , <b>2015</b> , 87, 210-3	1.6	12
48	Sexual Dysfunction in Men and Women. <b>2016</b> , 785-830		1
47	The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction. <i>Translational Andrology and Urology</i> , <b>2016</b> , 5, 181-6	2.3	7
46	Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review. <i>Research and Reports in Urology</i> , <b>2016</b> , 8, 123-31	1.3	11
45	Molecular and functional characterization of Kv 7 channels in penile arteries and corpus cavernosum of healthy and metabolic syndrome rats. <i>British Journal of Pharmacology</i> , <b>2016</b> , 173, 1478-90	8.6	21
44	Management of erectile dysfunction in men with diabetes. <b>2016</b> , 210-219		
43	Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). <i>Journal of Sexual Medicine</i> , <b>2016</b> , 13, 465-88	1.1	110
42	Sexual habits of men with ED who take phosphodiesterase 5 inhibitors: a survey conducted in 7 countries. <i>International Journal of Clinical Practice</i> , <b>2018</b> , 72, e13074	2.9	6
41	Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. <i>LUTS: Lower Urinary Tract Symptoms</i> , <b>2018</b> , 10, 84-92	1.9	17
40	Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson Disease?. <i>Molecular Neurobiology</i> , <b>2018</b> , 55, 822-834	6.2	19
39	Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction. <i>Sexual Medicine Reviews</i> , <b>2018</b> , 6, 242-252	5.6	53
38	Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents. <i>Ecancermedicalscience</i> , <b>2018</b> , 12, 824	2.7	24
37	Sildenafil (Viagra <sup>TM</sup> ): Synthesis Step by Step and its Pharmaceutical Importance in Diabetic Patients with Erectile Dysfunction. <b>2018</b> , 08,		1
36	Tadalafil ?. <b>2018</b> ,		
35	Management of erectile dysfunction. <b>2018</b> , 545-554		
34	Multilevel analyses of on-demand medication data, with an application to the treatment of Female Sexual Interest/Arousal Disorder. <i>PLoS ONE</i> , <b>2019</b> , 14, e0221063	3.7	1
33	cis-Selective synthesis of 1,3-disubstituted tetrahydro- $\beta$ -carbolines from N-sulfonyl N,S-acetals. <i>Organic and Biomolecular Chemistry</i> , <b>2019</b> , 17, 9510-9513	3.9	1

32	Structure of Human Phosphodiesterase 5A1 Complexed with Avanafil Reveals Molecular Basis of Isoform Selectivity and Guidelines for Targeting $\beta$ -Helix Backbone Oxygen by Halogen Bonding. <i>Journal of Medicinal Chemistry</i> , <b>2020</b> , 63, 8485-8494	8.3	3
31	Tadalafil ameliorates memory deficits, oxidative stress, endothelial dysfunction and neuropathological changes in rat model of hyperhomocysteinemia induced vascular dementia. <i>International Journal of Neuroscience</i> , <b>2020</b> , 1-13	2	6
30	Commentary RE: The International Index of Erectile Function (IIEF): A Multidimensional Scale for Assessment of Erectile Dysfunction. <i>Urology</i> , <b>2020</b> , 145, 308-309	1.6	0
29	Effect of tadalafil on penile nitric oxide synthase and corporal smooth muscle in rats under dutasteride treatment. <i>Aging Male</i> , <b>2020</b> , 23, 161-167	2.1	1
28	Natural Molecules as Talented Inhibitors of Nucleotide Pyrophosphatases/Phosphodiesterases (PDEs). <i>Current Topics in Medicinal Chemistry</i> , <b>2021</b> ,	3	0
27	The NO - K <sup>+</sup> channel axis in pulmonary arterial hypertension. Activation by experimental oral therapies. <i>Advances in Experimental Medicine and Biology</i> , <b>2003</b> , 543, 293-322	3.6	16
26	Cardiovascular Safety of Phosphodiesterase-5 Inhibitors. <b>2004</b> , 139-161		1
25	Erectile Dysfunction: Pharmacological Therapy. <b>2011</b> , 675-696		1
24	Sexual Dysfunction in Men and Women. <b>2011</b> , 778-816		2
23	A Review of Hypogonadism and Erectile Dysfunction Among HIV-Infected Men During the Pre- and Post-HAART Eras: Diagnosis, Pathogenesis, and Management. <i>AIDS Patient Care and STDs</i> , <b>2005</b> , 19, 869-885	5.8	1
22	Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated Analyses. <i>Journal of Urology</i> , <b>2002</b> , 1332-1336	2.5	35
21	Tadalafil and palpebral edema. <i>Southern Medical Journal</i> , <b>2004</b> , 97, 1142-3	0.6	8
20	Cyclic Nucleotide Phosphodiesterase Superfamily. <b>2006</b> ,		8
19	Phosphodiesterase 5. <b>2006</b> ,		8
18	Ameliorative Effect of Phosphodiesterase-5 Inhibitor in Rat Model of Vascular Dementia. <i>Current Neurovascular Research</i> , <b>2019</b> , 16, 27-39	1.8	5
17	Effect of tadalafil on erectile dysfunction in male patients with diabetes mellitus. <i>Vojnosanitetski Pregled</i> , <b>2007</b> , 64, 399-404	0.1	5
16	Tadalafil: A Comprehensive Update. <b>2004</b> , 2, 225-246		1
15	Therapie. <b>2002</b> , 129-246		

14	Phosphodiesterase-5. <b>2003</b> , 447-451		
13	Oral Type 5 Phosphodiesterase Therapy for Male and Female Sexual Dysfunction. <b>2004</b> , 107-119		
12	Erectile Dysfunction Assessment and Management in Primary Care Practice. <b>2005</b> , 149-183		
11	Erectile dysfunction in the aging man: current options for treatment. <i>Aging Health</i> , <b>2006</b> , 2, 71-86		○
10	Treatment of Erectile Dysfunction in Chronic Kidney Disease. <b>2008</b> , 783-790		
9	Alkylxanthines and Phosphodiesterase 4 Inhibitors for Allergic Diseases. <b>2009</b> , 105-132		
8	Management of Erectile Dysfunction. 134-145		
7	Phosphodiesterase-5 Inhibitors in Cardioprotection. <b>2013</b> , 439-458		
6	Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2004</b> , 1, 185-196		
5	Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. <i>Reviews in Urology</i> , <b>2003</b> , 5 Suppl 7, S9-S20	1	1
4	Cardiovascular/Stroke Risk Assessment in Patients with Erectile Dysfunction: A Role of Carotid Wall Arterial Imaging and Plaque Tissue Characterization Using Artificial Intelligence Paradigm: A Narrative Review. <i>Diagnostics</i> , <b>2022</b> , 12, 1249	3.8	○
3	Integration of Transcriptomics and Metabolomics Reveals the Antitumor Mechanism Underlying Tadalafil in Colorectal Cancer. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13,	5.6	
2	Effects of bariatric surgery on testosterone level and sexual function in men with obesity: A retrospective study. 13,		○
1	Development of a Rapid LC-MS/MS Method for Simultaneous Quantification of Donepezil and Tadalafil in Rat Plasma: Its Application in a Pharmacokinetic Interaction Study after Oral Administration in Rats. <b>2023</b> , 28, 2352		○